NEWSpublisher 2007 :: AngloChinese Investments
date from:
date to:
search for string:
» 23/07/2009 [Company watch]
China Aoxing Pharmaceutical Corp. Receives Renewal of GMP Certification for Capsule Dosage Form of Pharmaceutical Products
» 15/03/2010 [Industry news]
Recordati S.p.A And Lee Pharmaceutical Announce Partnership For Zanidip(R) In China
» 26/10/2009 [Finance]
China Growth to Remain Fast in Fourth Quarter, Official Says
» 17/08/2009 [Industry news]
Chindex Posts Profit on Product Sales, Health Services
» 07/05/2010 [Industry news]
Hong Kong: Recall of all products manufactured by Quality Pharmaceutical Lab Ltd
COMPANY NEWS back to previous page show list
»21/03/2010 [Industry news]
China Offers Lion Share of Emerging Market Growth

IMS Health has upped its count of “pharmerging” countries to 17 high-growth pharmaceutical markets.

by: ChinaBio Today , IMS Health has upped its count of “pharmerging” countries to 17 high-growth pharmaceutical markets. Previously, only seven markets qualified. According to IMS Health, these 17 countries represent $90 billion of increased pharmaceutical spending during 2009-13, collectively offering 48% of the growth in the worldwide market in 2013. China is the most significant opportunity of the 17, a market that is “in a league of its own” in the words of the healthcare consultancy company. Shanghai Zhangjiang Biotech & Pharmaceutical Base Development Company has signed a cooperation agreement with Sweden’s Uppsala BIO and Uppsala Innovation Centre. MicuRx Pharmaceuticals filed an Investigational New Drug (IND) application with the SFDA for MRX-I, its most-advanced antibiotic drug candidate. Novartis AG , the Swiss multinational pharma, said revenues in China grew 36% last year, far better than the company’s overall 11% rise in sales. China Sky One Medical expects 2010 revenues to grow by 20% to $156 million. Net income, however, will increase by a more modest 13% to $39 million, as the company ups its R&D to 15% of revenue. Vycor Medical, Inc.will seek SFDA approval for its VBAS (ViewSite™ Brain Access System), an innovative retraction system for use during brain surgery. Lee Pharmaceutical Holdings, which is headquartered in Hong Kong, signed an exclusive license for China distribution of a Recordati S.p.A. [MI: RECI] antihypertensive drug, Zanidip® (lercanidipine). Zanidip is a calcium channel blocker. The FDA has told XiAn Libang Pharmaceuticals to improve its quality control procedures, if it wants to continue importing products to the US. The US agency told the company to hire an outside auditor to develop a Corrective Action Plan and respond to the warning letter within 15 days.

AngloChinese Investments ltd.
Home | Company news | TOP 50 | Events | About us
C&F Bright Solutions ltd.